A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
David R. Wise, Kwok‐Kin Wong(NYU Langone Health), Cynthia A. Sirard(Leeds Teaching Hospitals NHS Trust), Jiehui Deng(NYU Langone Health), Jonathan Melamed(Long Island University), Erika Waalkes(NYU Langone Health), Viktoriya Aranchiy(NYU Langone Health), Pratip K. Chattopadhyay(National Institute of Allergy and Infectious Diseases), Michael Haas(Harvard University), Michael H. Kagey, Amrutesh S. Puranik(NYU Langone Health), Cynthia A. Loomis(New York University), Gabrielle Gargano(NYU Langone Health), Luis Chiriboga(Columbia University Irving Medical Center), Sarah Griglun(NYU Langone Health), Victor Adorno Febles(VA NY Harbor Healthcare System), Shanmugapriya Selvaraj(NYU Langone Health), Arjun Vasant Balar(NYU Langone Health), Fang‐Ming Deng(East China Jiaotong University), Jason Baum, Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Dayna Leis(NYU Langone Health), Russell K. Pachynski, Walter Newman(Ensemble Therapeutics (United States)), Minas P. Economides(NYU Langone Health), Nadia Soamchand(NYU Langone Health), Ezeddin Fedal(New York University), Nina Yang(NYU Langone Health), Sabrina Rocha Machado(NYU Langone Health), Samuel R. Denmeade(Johns Hopkins University), Qinghu Ren(J. Craig Venter Institute), Andrea B. Troxel(Andover Eye Associates)
Cited by 9
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k